Rarity Bioscience AB

https://www.raritybioscience.com

LinkedIn: https://www.linkedin.com/company/rarity-bioscience

Rarity Bioscience was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology, based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology. Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples, enabling full potential of liquid biopsies and radically improving cancer diagnostics. *

	Start	2021-01-01 established (s-off)
	Predecessor	University of Uppsala (Uppsala University)
	Industry	molecular diagnostics
	Industry 2	superRCA technology (for mutation detection from liquid biopsies)
	Person	Bosaeus, Linus (Rarity Bioscience 202302 CEO)

	Region	Uppsala
	Country	Sweden
	Street	3 Husargatan BMC C10;1
	City	75237 Uppsala
	Tel	+46-73-822-2287
		Address record changed: 2023-02-07

Basic data	Employees	n. a.

		* Document for »About Section«: Novalis Biotech. (2/6/23). "Press Release: Novalis Biotech Invests in Rarity Bioscience’s Ultra Sensitive Genomics Technology". Uppsala.

		Record changed: 2024-02-12